Inflammatory Bowel Disease (IBD) pharmacotherapy and the risk of serious infection: a systematic review and network meta-analysis

• Published in: BMC gastroenterology 2017-04, Vol.17 (1), p.52-52, Article 52
• Main Authors: Wheat, Chelle L, Ko, Cynthia W, Clark-Snustad, Kindra, Grembowski, David, Thornton, Timothy A, Devine, Beth
• Format: Article
• Language: English
• Subjects: Adrenal Cortex Hormones - therapeutic use; Anti-Bacterial Agents - therapeutic use; Anti-Inflammatory Agents, Non-Steroidal - therapeutic use; Antibiotics; Biological Products - therapeutic use; Drug therapy; Gastroenterology; Humans; IBD pharmacotherapy; Immunologic Factors - therapeutic use; Infection; Infections; Infections - epidemiology; Inflammation; Inflammatory bowel disease; Inflammatory Bowel Diseases - drug therapy; Meta-analysis; Network Meta-Analysis; Randomization; Risk Factors; Studies; Tuberculosis
• ISSN: 1471-230X; 1471-230X
• DOI: 10.1186/s12876-017-0602-0

The magnitude of risk of serious infections due to available medical therapies of inflammatory bowel disease (IBD) remains controversial. We conducted a systematic review and network meta-analysis of the existing IBD literature to estimate the risk of serious infection in adult IBD patients associated with available medical therapies. Studies were identified by a literature search of PubMed, Cochrane Library, Medline, Web of Science, Scopus, EMBASE, and ProQuest Dissertations and Theses. Randomized controlled trials comparing IBD medical therapies with no restrictions on language, country of origin, or publication date were included. A network meta-analysis was used to pool direct between treatment comparisons with indirect trial evidence while preserving randomization. Thirty-nine articles fulfilled the inclusion criteria; one study was excluded from the analysis due to disconnectedness. We found no evidence of increased odds of serious infection in comparisons of the different treatment strategies against each other, including combination therapy with a biologic and immunomodulator compared to biologic monotherapy. Similar results were seen in the comparisons between the newer biologics (e.g. vedolizumab) and the anti-tumor necrosis factor agents. No treatment strategy was found to confer a higher risk of serious infection than another, although wide confidence intervals indicate that a clinically significant difference cannot be excluded. These findings provide a better understanding of the risk of serious infection from IBD pharmacotherapy in the adult population. The protocol for this systematic review was registered on PROSPERO ( CRD42014013497 ).